April 28th 2024
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Analysis Supports Association Between TKI Response and Longer OS in HCC
January 22nd 2019Achieving an objective response to TKI therapy was associated with longer overall survival in patients with previously untreated hepatocellular carcinoma, according to findings of a retrospective analysis presented during the 2019 Gastrointestinal Cancers Symposium.
Read More
Expert Discusses Research Using Ceramide Liposome Particles With Immunotherapy to Treat HCC
December 22nd 2018Kevin Staveley-O’Carroll, MD, PhD, discusses how the field of HCC has advanced over the last few years and how a mouse model at the University of Missouri is being used to further investigate immunotherapy treatment options.<br />
Read More
Pishvaian Highlights Potential Role for Immunotherapy in Frontline HCC Treatment
December 21st 2018Michael J. Pishvaian, MD, PhD, discusses the potential for atezolizumab and bevacizumab in the frontline setting of HCC, as well the overall impact of immunotherapy in the treatment landscape of HCC.
Read More
Pivotal Phase III Trial Initiated to Investigate Role of Cabozantinib in Advanced HCC
December 14th 2018A large pivotal phase III trial has been initiated to evaluate the potential for the first-line combination of cabozantinib and atezolizumab in comparison with standard-of-care sorafenib for patients with advanced hepatocellular carcinoma. Exelixis and Ipsen, the companies developing cabozantinib, announced the COSMIC-312 trial last week.
Read More
Nivolumab Offers New Treatment Option for Patients with Child-Pugh B Advanced HCC
November 16th 2018Results from the phase I/II CheckMate 040 study demonstrated that single-agent nivolumab showed promising clinical activity in patients with Child-Pugh B advanced hepatocellular carcinoma, a population often excluded from advanced HCC trials.
Read More
Current Agents Approved for Treatment of HCC
November 15th 2018Ghassan Abou-Alfa, MD, discusses the approved agents available for the treatment of hepatocellular carcinoma. Compared to 2007 when there was only 1 agent available, sorafenib, there is now a great number of options for these patients.
Watch
Atezolizumab/Bevacizumab Combination Demonstrates Durable Responses in Advanced HCC
November 7th 2018Combining atezolizumab (Tecentriq) with bevacizumab (Avastin) induced promising and durable antitumor activity in patients with advanced hepatocellular carcinoma, according to findings from a phase Ib study presented during the 2018 ESMO Congress.
Read More
Etiology of HCC Plays a Critical Role in Treatment Choice as Landscape Grows, Says Mody
November 2nd 2018Kabir Mody, MD, discusses the evolution of the hepatocellular carcinoma treatment landscape over the past year during a presentation at the 2018 International Society of Gastrointestinal Oncology.
Read More